Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital

Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies - A Danish population-based cohort study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Distinct patterns of comorbidity prior to diagnosis of incident systemic lupus erythematosus in the Danish population

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Intestinal permeability in type 1 diabetes: An updated comprehensive overview

    Research output: Contribution to journalReviewResearchpeer-review

  3. GPR15+ T cells are Th17 like, increased in smokers and associated with multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Nutritional recommendations for gout: An update from clinical epidemiology

    Research output: Contribution to journalReviewResearchpeer-review

  • Mohamed Attauabi
  • Jakob Benedict Seidelin
  • Oluf Krautwald Felding
  • Mads Damsgaard Wewer
  • Laura Kirstine Vinther Arp
  • Melek Zahra Sarikaya
  • Alexander Egeberg
  • Nora Vladimirova
  • Flemming Bendtsen
  • Johan Burisch
View graph of relations

Background: Limited data exist regarding the disease course of coronavirus disease 2019 (COVID-19) and its relationship with immunosuppressants among patients with immune-mediated inflammatory diseases (IMIDs). Therefore, this study aims to investigate the association between COVID-19, frequent rheumatological, dermatological, gastrointestinal, and neurological IMIDs and immunosuppressants. Methods: We conducted a Danish population-based cohort study including all residents living within Capital Region of Denmark and Region Zealand from January 28th, 2020 until September 15th, 2020 with the only eligibility criterion being a test for SARS-CoV-2 via reverse transcription–polymerase chain-reaction. Main outcomes included development of COVID-19, COVID-19-related hospitalization and mortality. Results: COVID-19 was less common among patients with IMIDs than the background population (n = 328/20,513 (1.60%) and n = 10,792/583,788(1.85%), p < 0.01, respectively). However, those with IMIDs had a significantly higher risk of COVID-19-related hospitalization (31.1% and 18.6%, p < 0.01, respectively) and mortality (9.8% and 4.3%, p < 0.01, respectively), which were associated with patients older than 65 years, and presence of comorbidities. Furthermore, systemic steroids were independently associated with a severe course of COVID-19 (Odds ratio (OR) = 3.56 (95%CI 1.83–7.10), p < 0.01), while biologic therapies were associated with a reduced risk hereof (OR = 0.47 (95%CI 0.22–0.95), p = 0.04). Patients suspending immunosuppressants due to COVID-19 had an increased risk of subsequent hospitalization (OR = 3.59 (95%CI 1.31–10.78), p = 0.02). Conclusion: This study found a lower occurrence, but a more severe disease course, of COVID-19 among patients with IMIDs, which was associated with the use of systemic steroids for IMIDs and suspension of other immunosuppressants. This study emphasizes the importance of weighing risks before suspending immunosuppressants during COVID-19.

Original languageEnglish
Article number102613
JournalJournal of Autoimmunity
Pages (from-to)1-8
Number of pages8
Publication statusPublished - Mar 2021

Bibliographical note


    Research areas

  • Autoimmune diseases, COVID-19, Epidemiology, Immune-mediated inflammatory diseases, Immunosuppressive agents, Population-based, Age Factors, COVID-19 Nucleic Acid Testing, Humans, Middle Aged, Risk Factors, Immunosuppressive Agents/administration & dosage, Male, COVID-19/diagnosis, Inflammation/diagnosis, Denmark/epidemiology, Immunosuppression, SARS-CoV-2, Adult, Female, Aged

ID: 62310174